Join the 'Myrbetriq' group to help and get support from people like you.
Posted 19 Jan 2015 by Drugs.com
MONDAY, Jan. 19, 2015 – More than 33 million Americans suffer from overactive bladder, including 40 percent of women and 30 percent of men, the U.S. Food and Drug Administration says. There are numerous approved treatments for the condition, but many people don't seek help because they're embarrassed or don't know about therapy options, according to an agency news release. In people with overactive bladder, the bladder muscle squeezes too often or squeezes without warning. This can cause symptoms such as: the need to urinate too often (eight or more times a day, or two or more times a night); the need to urinate immediately; or accidental leakage of urine. Treatments for overactive bladder include oral medications, skin patches or gel, and bladder injections. "There are many treatment options for patients with overactive bladder. Not every drug is right for every patient," Dr. Olivia ... Read more
Related support groups: Overactive Bladder, Urinary Incontinence, Oxybutynin, Botox, VESIcare, Myrbetriq, Ditropan, Oxytrol, Enablex, Detrol, Sanctura, Trospium, Solifenacin, Detrol LA, Mirabegron, Gelnique, Sanctura XR, Tolterodine, Onabotulinumtoxina, Darifenacin
Posted 7 Jan 2015 by Drugs.com
TUESDAY, Jan. 6, 2015 – A drug already used to treat overactive bladder may also someday help control weight by boosting the metabolic powers of brown fat, a small study suggests. While white fat stores energy, brown fat burns energy to generate body heat. In the process, it can help maintain body weight and prevent obesity, at least in animals, previous studies have shown. In the new study, researchers gave 12 healthy, lean young men a high dose of the drug mirabegron (Myrbetriq), and found that it boosted their metabolic rate. The drug "activates the brown fat cells to burn calories and generate heat," said study researcher Dr. Aaron Cypess. He is section head of translational physiology at the U.S. National Institute of Diabetes and Digestive and Kidney Diseases. When the activity of the drug peaked, "the metabolic rate went up by 13 percent on average," Cypess said. That translates ... Read more